Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial

Clinical utility of commercial multi-gene pharmacogenetic tests in depression is starting to be studied with some promising results on efficacy and tolerability. Among the next steps is the definition of the patient profile that is most likely to benefit from testing. Here we present a reanalysis of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neural Transmission 2019-01, Vol.126 (1), p.95-99
Main Authors: Menchón, J. M., Espadaler, J., Tuson, M., Saiz-Ruiz, J., Bobes, J., Vieta, E., Álvarez, E., Pérez, V.
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
NCT
NCT02529462
Neurology
Neurosciences
Psychiatry
Psychiatry and Preclinical Psychiatric Studies - Original Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical utility of commercial multi-gene pharmacogenetic tests in depression is starting to be studied with some promising results on efficacy and tolerability. Among the next steps is the definition of the patient profile that is most likely to benefit from testing. Here we present a reanalysis of data from the AB-GEN randomized clinical trial showing that clinical utility of pharmacogenetic testing can be markedly influenced by patient characteristics such as age, baseline severity and duration of current depressive episode. Trial registration ClinicalTrials.gov NCT02529462.
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-018-1879-z